Head to Head Comparison: XORTX Therapeutics (XRTX) versus The Competition

XORTX Therapeutics (NASDAQ:XRTX) is one of 247 public companies in the “MED – DRUGS” industry, but how does it weigh in compared to its rivals? We will compare XORTX Therapeutics to related businesses based on the strength of its dividends, profitability, analyst recommendations, institutional ownership, valuation, earnings and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for XORTX Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1	0	0	0	1.00
XORTX Therapeutics Competitors	2822	4042	10306	466	2.48

As a group, “MED – DRUGS” companies have a potential upside of 49.11%. Given XORTX Therapeutics’ rivals stronger consensus rating and higher probable upside, analysts clearly believe XORTX Therapeutics has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares XORTX Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
XORTX Therapeutics	N/A	-$2.66 million	-0.76
XORTX Therapeutics Competitors	$1.17 billion	$100.39 million	-4.65

XORTX Therapeutics’ rivals have higher revenue and earnings than XORTX Therapeutics. XORTX Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 44.1% of shares of all “MED – DRUGS” companies are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by insiders. Comparatively, 13.6% of shares of all “MED – DRUGS” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

XORTX Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, XORTX Therapeutics’ rivals have a beta of -0.38, meaning that their average stock price is 138% less volatile than the S&P 500.

Profitability

This table compares XORTX Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-120.32%	-90.53%
XORTX Therapeutics Competitors	-22,657.47%	-150.19%	-22.81%

Summary

XORTX Therapeutics rivals beat XORTX Therapeutics on 9 of the 13 factors compared.

About XORTX Therapeutics

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.